Payment overview · 2025
General Payments
$3,804.67
155 reported records · 29 companies
Healthcare provider profile · identity verified
Marcella Rowley, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · RIVERTON, UT · NPI 1740301837
Verified facts
What the public records show
CMS Open Payments records show Marcella Rowley, FNP received $3,804.67 in general payments during 2025 across 155 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $480.76 | 12.6% | 13 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $469.89 | 12.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $386.06 | 10.2% | 23 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $343.74 | 9.0% | 12 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $330.11 | 8.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $317.65 | 8.3% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.14 | 7.1% | 22 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $188.95 | 5.0% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $188.14 | 4.9% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $107.30 | 2.8% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.26 | 2.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.40 | 2.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.57 | 1.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.49 | 1.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.06 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.33 | 1.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.18 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.96 | 1.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.20 | 0.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.94 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.12 | 0.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.94 | 0.7% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $21.03 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.25 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.11 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 0.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.69 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.20 | 0.4% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $6.02 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,317.68 | 151 |
| Consulting Fee | $350.00 | 2 |
| Education | $136.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $469.89 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $386.06 | 23 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $361.61 | 20 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $330.11 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $293.72 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $264.23 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $227.41 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $226.79 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $188.95 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $188.14 | 8 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $176.61 | 9 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.92 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $119.23 | 10 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $119.01 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $107.30 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $94.26 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.73 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.40 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $68.57 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $63.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.33 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $6.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 131 |
| Liothyronine Sodium | Liothyronine Sodium | 258 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 47 |
| Progesterone | Progesterone, Micronized | 149 | 41 |
| Metformin Hcl Er | Metformin Hcl | 134 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 16 |
| Alprazolam | Alprazolam | 115 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 109 | 35 |
| Mounjaro | Tirzepatide | 99 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | 14 |
| Gabapentin | Gabapentin | 82 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 23 |
| Omeprazole | Omeprazole | 80 | 21 |
| Montelukast Sodium | Montelukast Sodium | 78 | 29 |
| Fluconazole | Fluconazole | 75 | 39 |
| Bupropion Xl | Bupropion Hcl | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 14 |
| Jardiance | Empagliflozin | 66 | 18 |
| Ozempic | Semaglutide | 65 | 17 |
| Trazodone Hcl | Trazodone Hcl | 63 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 26 |
| Famotidine | Famotidine | 61 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 19 |
| Lisinopril | Lisinopril | 59 | 19 |
| Armour Thyroid | Thyroid,pork | 56 | 15 |
| Lactated Ringers | Ringer's Solution,lactated | 56 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 15 |
| Magnesium Sulfate | Magnesium Sulfate | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 21 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 48 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 21 |
| Irbesartan | Irbesartan | 47 | 13 |
| Celecoxib | Celecoxib | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 13 |
| Valacyclovir | Valacyclovir Hcl | 45 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Estradiol | Estradiol | 43 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 40 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 37 | 11 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 36 | 16 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Losartan Potassium | Losartan Potassium | 33 | 12 |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Hydrocortisone | Hydrocortisone | 31 | 11 |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 12 |
| Finasteride | Finasteride | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | 12 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Nystatin | Nystatin | 29 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Eliquis | Apixaban | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Furosemide | Furosemide | 26 | 12 |
| Prednisone | Prednisone | 26 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | 13 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Dotti | Estradiol | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Estradiol Valerate | Estradiol Valerate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 11 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,804.67 · 155 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, JOURNAVX, Kerendia, Korlym, LEQVIO, LINZESS, LUMRYZ, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SYNTHROID, Sunosi, Symbravo, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, XIFAXAN, XYREM, XYWAV, ZAVZPRET, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error